Hot Investor Mandate 2: Corporate Fund Seeks Therapeutics and Medical Devices in Oncology, Immunology and Hematology

~ Next Phase Admin ~ Leave a comment

A corporate VC firm that invests strategically on behalf of a biopharmaceutical company invests in life science companies typically at the series A-B stage; initial allocations are generally of about $5 million, with the potential for $10-15 million over the life of an investment. The firm is open to opportunities worldwide.

The firm invests in three indication areas: oncology, immunology, and hematology. The fund is interested in therapeutic, medical device and healthcare IT opportunities in these three areas, but does not invest in diagnostics. The firm is open to investing in companies developing products that have not yet undergone clinical trials, provided that proof of concept data from preclinical studies has been attained (or prototype data in the case of medical devices).

The firm has no set requirements for companies and management teams; applications to the fund are assessed by a triage process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: US VC Seeks HCIT, Health Services, and Life Science Companies

~ Next Phase Admin ~ Leave a comment

A US-based venture capital firm established in 2014 invests in a variety of sectors including healthcare services, biotech, and medical devices. The firm typically invests $50K-$500K per company and prefers to lead investments. The firm is seeking 1-2 new investments within the next year and is open to companies based in the U.S.

The firm is open to all sectors of life science technology, though has a particular interest in healthcare services and software; therapeutics and drug discovery; and diagnostics and devices. The firm typically looks at proof-of-concept technology, and is open to preclinical technology close to receiving IND and entering clinical trials. The firm is indication agnostic.

The firm typically seeks companies that have under $5M pre-money valuations, and takes a board seat after an investment.     

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Biotech Firm Seeks Therapeutics In Oncology, Dermatology, Rare Diseases, and Acute Care

~ Next Phase Admin ~ Leave a comment

A NASDAQ-listed company which acquires, develops and commercializes promising drugs and technologies is seeking asset partnerships. The firm provides partners with committed investment capital, experienced start-up management, world-class scientific expertise, and shared facilities. The firm does not make typical equity investments, but rather is open to a variety of deal structures to acquire or co-develop assets, including traditional milestone-based licensing deals, joint ventures, option agreements and equity arrangements (no less than 50% equity stake).

The company focuses primarily on therapeutic opportunities, but will consider diagnostic and medical devices that are based on compelling science. Current areas of interest include dermatology, rare diseases, oncology, acute care, and specialist products (eg. in hepatology, GI, women’s health).

The firm has no management team requirements and will work with entrepreneurs of all experience levels coming from academia or industry, and has no restriction on the geographic location of companies or technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

RESI@TMCx Innovation Challenge: Participating Startups Announced

~ Next Phase Admin ~ Leave a comment

By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

Shaoyu 10*10

It’s time to announce the successful applicants to the RESI@TMCx Innovation Challenge. LSN’s scientific review board have assessed and ranked all entrants across a wide range of criteria, from scientific novelty to strength of IP, to select the 30 strongest entrants. These entrepreneurs will receive a presentation space in the RESI@TMCx exhibit hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. All RESI attendees have the opportunity to vote in the Innovation Challenge by “investing” in the best of these companies.

If your company missed this opportunity to compete in the RESI@TMCx Innovation Challenge, you can now enter the RESI on MaRS Innovation Challenge, to be held on June 23rd in Toronto.

 

Going To a Conference? Follow These Four Tips for Partnering Success

~ Next Phase Admin ~ Leave a comment

By Jay Doherty, Business Development, LSN

jay

Like many players in healthcare, the Life Science Nation team travel around the world to attend partnering conferences and build dialogue with investors and fundraising CEOs. We’ve had the opportunity to see both the best and the worst in partnering, and have also heard from investors about what catches their attention in a partnering message. Last year, LSN provided a template partnering message designed to increase your response rate when reaching out to investors. Here are some additional tips for successful partnering requests:

Be brief and concise in your outreach. Investors want to see enough information to entertain a meeting, but will not spend all day reading an introductory email. Hit the points you need to and ask for a meeting.

Follow up on your requests. If you have not heard back after a few days, send another message, and follow up with a phone call if possible. Investors are flooded with emails daily and cannot catch every one. Being persistent and politely resending a request will likely get an answer, and hopefully a meeting, quicker than leaving it to chance.

Do not be deterred by a full schedule. Investor schedules will fill up for a partnering event, but that does not mean they absolutely have no time to chat. Be proactive, suggest an ad hoc meeting, or a quick introduction throughout the course of the day. You might not get every meeting you want, but getting in front of an investor for a brief moment will better your chances of securing a meeting down the road.

Make sure you set yourself up for the future. Do not forget to get an investor’s contact information at the end of the meeting. Even if you’re not a fit for their current investment preferences, they might be able to connect the dots for you elsewhere.

By sticking to these fundamentals, you can make it easier for an investor to identify you as a fit for their investment strategy. This will lead to higher response rates and more productive meetings.

RESI@TMCx Panel Announcement: Incubators, Accelerators & New Models

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, Director of Research, LSN

With the explosion of activity in early stage life sciences in the last few years, many new programs have been formed to support the youngest new biotech, medtech and healthcare IT companies in developing their products and making first steps toward commercialization.

This RESI panel will highlight five programs that provide vital resources at the earliest stage, including support, work space, mentoring, business education, and investment. The panelists will talk about how they select companies, how they help entrepreneurs turn scientific ideas into commercial success stories, and what makes each of their programs unique.

Moderated by Atul Varadhachary, Managing Partner, Fannin Innovation Studio, this session will feature:

Hot Investor Mandate 1: China-based Fund Seeks Therapeutic Opportunities Worldwide

~ Next Phase Admin ~ Leave a comment

A sector-exclusive life sciences venture and growth equity fund based in Shanghai, China, manages 5 funds with AUM of USD 500M. The firm currently investing from a fund that closed in April 2015, backed by a pharma firm as well as a number of world-class institutional investors. The firm is stage agnostic, investing in early, growth, and up to pre-IPO opportunities. The firm’s team of investment professionals all have a healthcare background. Investment size is USD 5-45 million per company. The firm prefers to lead or co-lead a financing round, and typically requires a board seat. With both USD and RMB funds, the firm on China but also considers opportunities from US, Canada, and Europe.

The firm focuses 75% on therapeutics, with an emphasis on oncology, cell therapy, and biologics. Small molecules are less of interest. The firm is also interested in medical devices, diagnostics, animal health. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com